About: Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments
Creator	Dong, Ying Sun, Jing Bai, Fan Qin, Fan Zhang, Xue-Fang Zhao, Yan-Hong Zhao, Yan-Qiu
Source	PMC
abstract	Chronic myeloid leukemia (CML) is characterized by the accumulation of active BCR-ABL protein. Imatinib is the first-line treatment of CML; however, many patients are resistant to this drug. In this study, we aimed to compare the differences in expression patterns and functions of time-series genes in imatinib-resistant CML cells under different drug treatments. GSE24946 was downloaded from the GEO database, which included 17 samples of K562-r cells with (n=12) or without drug administration (n=5). Three drug treatment groups were considered for this study: arsenic trioxide (ATO), AMN107, and ATO+AMN107. Each group had one sample at each time point (3, 12, 24, and 48 h). Time-series genes with a ratio of standard deviation/average (coefficient of variation) >0.15 were screened, and their expression patterns were revealed based on Short Time-series Expression Miner (STEM). Then, the functional enrichment analysis of time-series genes in each group was performed using DAVID, and the genes enriched in the top ten functional categories were extracted to detect their expression patterns. Different time-series genes were identified in the three groups, and most of them were enriched in the ribosome and oxidative phosphorylation pathways. Time-series genes in the three treatment groups had different expression patterns and functions. Time-series genes in the ATO group (e.g. CCNA2 and DAB2) were significantly associated with cell adhesion, those in the AMN107 group were related to cellular carbohydrate metabolic process, while those in the ATO+AMN107 group (e.g. AP2M1) were significantly related to cell proliferation and antigen processing. In imatinib-resistant CML cells, ATO could influence genes related to cell adhesion, AMN107 might affect genes involved in cellular carbohydrate metabolism, and the combination therapy might regulate genes involved in cell proliferation.
has issue date	2017-08-08(xsd:dateTime)
bibo:doi	10.1007/s11596-017-1781-1
bibo:pmid	28786057
has license	no-cc
sha1sum (hex)	521a647145ffb1cefd8783cb1395719ad374e53f
schema:url	https://doi.org/10.1007/s11596-017-1781-1
resource representing a document's title	Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments
has PubMed Central identifier	PMC7088819
has PubMed identifier	28786057
schema:publication	J Huazhong Univ Sci Technolog Med Sci
resource representing a document's body	covid:521a647145ffb1cefd8783cb1395719ad374e53f#body_text
is schema:about of	named entity 'CML' named entity 'Miner' named entity 'involved' named entity 'group' named entity 'cells' named entity 'group' named entity 'compare' named entity 'time point' named entity 'cell proliferation' named entity 'study' named entity 'genes' named entity 'cell adhesion' named entity 'functions' named entity 'CELLS' named entity 'BASED' named entity 'K562' named entity 'DATABASE' named entity 'SAMPLE' named entity 'CELLULAR CARBOHYDRATE METABOLIC PROCESS' named entity 'RIBOSOME' named entity 'TIME' named entity 'SAMPLES' covid:arg/521a647145ffb1cefd8783cb1395719ad374e53f named entity 'REVEALED' named entity 'IMATINIB' named entity 'STUDY' named entity 'AMN107' named entity 'ACCUMULATION' named entity 'ARSENIC TRIOXIDE' named entity 'PERFORMED' named entity 'GROUPS' named entity 'ANTIGEN PROCESSING' named entity 'PATIENTS' named entity 'MOST OF' named entity 'MINER' named entity 'COMBINATION THERAPY' named entity '283' named entity 'TO DETECT' named entity 'TO COMPARE' named entity 'IMATINIB' named entity 'TIME' named entity 'CHRONIC MYELOID LEUKEMIA' named entity 'REGULATE' named entity 'DIFFERENT' named entity 'EXTRACTED' named entity 'DAB2' named entity 'TIME POINT' named entity 'DAVID' named entity 'VARIATION' named entity 'TREATMENTS' named entity 'ATO' named entity 'ACTIVE' named entity 'TREATMENTS' named entity 'RESISTANT' named entity 'DIFFERENT' named entity 'INFLUENCE' named entity 'TREATMENT' named entity 'RATIO' named entity 'CELL PROLIFERATION' named entity 'RESISTANT' named entity 'GROUP' named entity 'DRUG ADMINISTRATION' named entity 'ASSOCIATED WITH' named entity '3D5' named entity 'GENES' named entity 'STANDARD DEVIATION' named entity 'CML' named entity 'BCR-ABL PROTEIN' named entity 'CATEGORIES' named entity 'ENRICHED' named entity 'CCNA2' named entity 'FUNCTIONAL ENRICHMENT ANALYSIS' named entity 'FUNCTIONS' named entity 'GEO' named entity 'AP2M1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software